ClinicalTrials.gg
RecruitingNCT06643845INCREDIBLEUpdated May 22, 2026

Is Non Surgical CaRE Using Treat to Target Multimodal meDIcal Strategies aBLE to Delay or Avoid Total Knee Replacement?

An interventional study of arthroplasty and Medical and non-medical treatments in Osteoarthritis, Knee, sponsored by University Hospital, Brest. Recruiting at 21 sites in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by University Hospital, Brest · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Osteoarthritis, Knee with a site in France — 23 open to participants now, 33 under way, 1 of them phase 3. Osteoarthritis, Knee · France.

Planned enrollment
Largest of 86
1,000 · median 106
Started
2025
with 5 others
No phase
58 of 124
13 open now
Primary completion
2031-04
later than 30 of 32 live
Registered
110th of 124
by date

Among the 124 studies in Osteoarthritis, Knee with a site in France, this one has the largest planned enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2025, is one of 58 with no phase, reaches primary completion later than 30 of the 32 other live ones, and was the 110th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

23 of the 124 studies in Osteoarthritis, Knee with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Osteoarthritis, Knee with a site in France, or all of them as a file.
02

Study summary

Knee is the most common site of osteoarthritis. Treatment of knee osteoarthritis starts with a full course of medical therapy, followed by surgery to replace the knee with a prosthesis if this strategy fails, or in advanced cases. However, the new recommendations of the French rheumatology society, which evaluate the various treatments and position them in the treatment plan, are not well known, and the definition of a complete treatment remains unclear. The vast majority of patients are therefore referred to a surgeon after having tried a small part of the therapeutic arsenal (generally analgesics and corticosteroid or hyaluronic acid infiltrations). The goal of this study is to to select patients most likely to gain from surgery and to develop strategies that avoid the need for major surgery.

Read the detailed description

Knee is the most common site of osteoarthritis. Treatment of knee osteoarthritis starts with a full course of medical therapy, followed by surgery to replace the knee with a prosthesis if this strategy fails, or in advanced cases.

However, the new recommendations of the French rheumatology society, which evaluate the various treatments and position them in the treatment plan, are not well known, and the definition of a complete treatment remains unclear. The vast majority of patients are therefore referred to a surgeon after having tried a small part of the therapeutic arsenal (generally analgesics and corticosteroid or hyaluronic acid infiltrations).

Yet medical treatment has proved effective, suggesting that it could prevent a significant number of total knee arthroplasties. In addition, osteoarthritis of the knee is associated with various co-morbidities (diabetes, cardiovascular) that medical treatment can minimize (diet, physical activity).

The effectiveness of knee prostheses has been demonstrated, but up to 20% of patients continue to experience pain, and surgical procedures induce rare but serious events. Prostheses can also be revised, and are expensive.

This research is designed for patients suffering from femoro-tibial osteoarthritis who have been proposed total knee replacement by a surgeon, and aims to develop strategies to avoid the need for major surgery until the medical treatment arsenal adapted to the patient's situation has been tried.

In the treatment of osteoarthritis, the impact of shared decision-making between rheumatologists, orthopaedic surgeons and the patient in the event of incomplete medical treatment has been shown to be important, as the decision is often modified after discussion.

The main objective of this prospective, randomized, pragmatic, non-blinded, multicenter study is to investigate whether shared decision-making coupled with multimodal medical strategies delays surgery by at least 2 years in most patients, with non-inferiority on pain and function, lower cost and fewer serious adverse events compared with total knee arthroplasty from the outset.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • Surgery
  • Arthroplasty
  • Total knee replacement
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-90 years old
  • Femoro-tibial osteoarthritis Kellgren stage stage≥ 2 without laxity in extension;
  • A proposal of total knee replacement by a surgeon;
  • No joint injection within 3 months;
  • Visual analogic score pain (VAS) >40/100 but \<90/100 or Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index function sub scale >40/100 at inclusion;
  • Wish to discuss medical care;
  • Able to consent and having signed a consent form.

Exclusion criteria

Exclusion Criteria:

  • or no indication to surgery or medical care (severe infection for example)
  • Inflammatory arthritis
  • Lack of social insurance
  • Symptomatic (VAS pain >40) contralateral knee or hip osteoarthritis (with or without replacement)
  • Pregnant or breastfeeding woman
  • Patient under court protection, guardianship, curatorship
  • Patient deprived of liberty
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Multimodal medical care arm

    In the medical care arm, rheumatologists will list previous treatment, ongoing treatment and then order validated treatment (corticosteroid or hyaluronic acid joint injection if necessary, physical activity and weight loss in the event of obesity, other non-drug treatments (insole, orthosis) as well as other drug treatments (pain killers or non steroidal anti-inflammatory drugs) including validated tools (personalized program, filmed sessions and digital exercise media for regular practice at home, motivational e-mails). At least one modification will be discussed in each domain (physical activity, weight loss, insole, orthosis, assistive device when walking, joint injection, pills -pain killer acetaminophen and opioids- nonsteroidal anti inflammatory drugs -with classical rules - and others)

    Other: Medical and non-medical treatments

  • Active comparator
    Surgery arm

    In the surgery arm, patients will have to plan, as initially suggested, their surgery (total knee arthroplasty)

    Procedure: arthroplasty

Interventions

  • Procedurearthroplasty

    In the surgery arm, patients will have their surgery (arthroplasty), as originally planned.

  • OtherMedical and non-medical treatments

    In the medical care arm, patients will follow multimodal medical strategies to prevent surgery in a population of patients with knee osteoarthritis having a first indication of knee prosthesis

06

What researchers measure

Primary outcomes

  1. Multimodal medical care osteoarthritis is non inferior (with a threshold of 15% for pain and function) to total knee arthroplasty in symptomatic radiographic knee osteoarthritis.

    The outcome relates to two scales which constitute the composite principal endpoint; * Visual Analogic Score pain, VAS (scale 0-100) * Western Ontario and McMaster Universities function, WOMAC (scale 0-100) Success is defined by a VAS AND WOMAC scale ≤40/100 at 2 years Failure is defined by a VAS pain OR WOMAC scale \&gt; 40/100 at 2 years.

    Time frame: 2 years

Secondary outcomes

  1. Study the proportion of delayed surgery in the medical group

    Number of cumulated surgery (yes/no) by month in the medical group

    Time frame: 2 years

  2. Study the proportion of patients with severe events induced by surgery

    Number of severe events (Who classification) in the surgical group.

    Time frame: 2 years

  3. Analyze the impact of physical activity on change of body mass by arm in the randomized population.

    Perform analyses of body mass on whole body densitometry

    Time frame: 2 years

  4. To compare analgesic use by arm.

    Analgesic use by class in milligram.

    Time frame: 2 years

  5. To compare the 0-2 years cost using the National Health Data System between the 2 groups.

    Cost in euro between 0-2

    Time frame: 0-2 years

  6. To compare the 2-5 cost using the National Health Data System between the 2 groups.

    Cost in euro between 2-5 years

    Time frame: 2-5 years

07

Study locations

2 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All collected data that underlie results in a publication

Supporting information: Study protocol

Time frame: Data will be available beginning five years and ending fifteen years following the final study report completion

Access criteria: Data access request will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2031, 66 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 66 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Oct 16, 2024
StartActual
Oct 17, 2025
Primary completionEst.
Apr 2031
CompletionEst.
Apr 2031
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06643845
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Oct 17, 2025
Primary completion
Apr 2031 (estimated)
Completion
Apr 2031 (estimated)
Last update
May 22, 2026

Study contacts

Alain Saraux, Pr
Contact
alain.saraux@chu-brest.fr
+33 2 98 34 72 70
Alain Saraux, Pr
principal investigator · CHU Brest

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion